Clinical Trial Update: Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing irinotecan plus cetuximab versus irinotecan alone in metastatic, EGFR-positive colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• ERBITUX (cetuximab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED